• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    SC 13G/A 1 tm2428137d12_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Ocular Therapeutix, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    67576A100

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

    ¨

    Rule 13d-1(b)

    Rule 13d-1(c)

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 67576A100 Page 2 of 14

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of immediately exercisable warrants (“Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 3 of 14

     

    1.

    Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 4 of 14

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 5 of 14

     

    1.

    Names of Reporting Persons

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 6 of 14

     

    1.

    Names of Reporting Persons

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 7 of 14

     

    1.

    Names of Reporting Persons

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 8 of 14

     

    1.

    Names of Reporting Persons

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    13,760,200 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    13,760,200 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    13,760,200 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.7% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 67576A100 Page 9 of 14

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Ocular Therapeutix, Inc.

     

    Item 1.    
      (a)

    Name of Issuer

     

    Ocular Therapeutix, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    24 Crosby Drive, Bedford, MA 01730

         
    Item 2.    
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

         
      (b)

    Address of Principal Business Office or, if none, Residence

     

    New York Office:                        Palo Alto Office:

     

    7 Bryant Park                                3340 Hillview Avenue

    23rd Floor                                       Palo Alto, CA 94304

    New York, NY 10018

         
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

         
      (e)

    CUSIP Number

     

    67576A100

         

     

     

     

     

    CUSIP No. 67576A100 Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
         
      Not applicable  
         
    Item 4. Ownership  
         
      (a) Amount beneficially owned as of September 30, 2024:  
           
            Venrock Healthcare Capital Partners III, L.P. 13,760,200(1)  
            VHCP Co-Investment Holdings III, LLC  13,760,200(1)  
            Venrock Healthcare Capital Partners EG, L.P.  13,760,200(1)  
            VHCP Management III, LLC  13,760,200(1)  
            VHCP Management EG, LLC  13,760,200(1)  
            Nimish Shah  13,760,200(1)  
            Bong Koh  13,760,200(1)  
             
      (b) Percent of class as of September 30, 2024:  
           
            Venrock Healthcare Capital Partners III, L.P.  8.7%(2)  
            VHCP Co-Investment Holdings III, LLC  8.7%(2)  
            Venrock Healthcare Capital Partners EG, L.P.  8.7%(2)  
            VHCP Management III, LLC  8.7%(2)  
            VHCP Management EG, LLC  8.7%(2)  
            Nimish Shah  8.7%(2)  
            Bong Koh  8.7%(2)  
             

      (c) Number of shares as to which the person has, as of September 30, 2024:  
           
        (i) Sole power to vote or to direct the vote:  
           
            Venrock Healthcare Capital Partners III, L.P. 0  
            VHCP Co-Investment Holdings III, LLC 0  
            Venrock Healthcare Capital Partners EG, L.P. 0  
            VHCP Management III, LLC 0  
            VHCP Management EG, LLC 0  
            Nimish Shah 0  
            Bong Koh 0  
             

     

     

     

     

    CUSIP No. 67576A100 Page 11 of 14

     

        (ii) Shared power to vote or to direct the vote:  
           
            Venrock Healthcare Capital Partners III, L.P. 13,760,200(1)  
            VHCP Co-Investment Holdings III, LLC 13,760,200(1)  
            Venrock Healthcare Capital Partners EG, L.P. 13,760,200(1)  
            VHCP Management III, LLC 13,760,200(1)  
            VHCP Management EG, LLC 13,760,200(1)  
            Nimish Shah 13,760,200(1)  
            Bong Koh 13,760,200(1)  

     

        (iii) Sole power to dispose or to direct the disposition of:  
           
            Venrock Healthcare Capital Partners III, L.P. 0  
            VHCP Co-Investment Holdings III, LLC 0  
            Venrock Healthcare Capital Partners EG, L.P. 0  
            VHCP Management III, LLC 0  
            VHCP Management EG, LLC 0  
            Nimish Shah 0  
            Bong Koh 0  
             

        (iv) Shared power to dispose or to direct the disposition of:  
           
            Venrock Healthcare Capital Partners III, L.P. 13,760,200(1)  
            VHCP Co-Investment Holdings III, LLC 13,760,200(1)  
            Venrock Healthcare Capital Partners EG, L.P. 13,760,200(1)  
            VHCP Management III, LLC 13,760,200(1)  
            VHCP Management EG, LLC 13,760,200(1)  
            Nimish Shah 13,760,200(1)  
            Bong Koh 13,760,200(1)  

     

      (1)Consists of (i) 1,452,408 shares and 652,048 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 145,272 shares and 65,235 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 9,170,101 shares and 2,275,136 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

      (2)This percentage is calculated based upon the sum of (i) 155,921,685 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024; and (ii) 2,992,419 shares issuable upon the exercise of the Warrants described in Footnote 1 above.

     

     

     

     

    CUSIP No. 67576A100 Page 12 of 14

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 67576A100 Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact      
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 67576A100 Page 14 of 14

     

    EXHIBITS

     

    A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on December 28, 2023)
       
    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed December 28, 2023)
       
    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on December 28, 2023)

     

     

    Get the next $OCUL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    More analyst ratings

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

      BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025. 2025 RBC Capital Markets Global Healthcare Conference, May 20, 2025 Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 2:35PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY HC Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ, May 20, 2025Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 4:30PM ETPresenter: Pravin

      5/14/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

      AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout SOL-R continues to have strong enrollment through streamlined, accelerated execution Cash balance of $349.7M as of March 31, 2025, with expected runway through topline data for SOL-1 and SOL-R and into 2028 BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharma

      5/5/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

      BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025. Upcoming Investor Conferences Citizens JMP Life Sciences Conference 2025:Fireside Chat Date: Wednesday, May 7, 2025Fireside Chat Time: 9:00 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY Bank of America 2025 Global Healthcare Conference:Fireside Chat Date: Tuesday, May 13, 2025Fireside Chat Time: 9:20 AM PTPresenter: Pravin U. Dugel, MD, Executive C

      4/29/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      5/12/25 8:50:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/27/24 4:43:51 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      12/18/23 4:52:33 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      5/12/25 8:50:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dugel Pravin sold $147,533 worth of shares (21,475 units at $6.87), decreasing direct ownership by 0.61% to 3,520,318 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:27:13 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Heier Jeffrey S. sold $21,029 worth of shares (3,061 units at $6.87), decreasing direct ownership by 1% to 265,998 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:25:32 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Ocular Therapeutix

      William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

      4/8/25 9:29:59 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

      RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

      3/18/25 7:53:57 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Ocular Therapeutix with a new price target

      Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      3/11/25 7:42:03 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ocular Therapeutix Inc.

      10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:47:55 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:06:05 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ocular Therapeutix Inc.

      DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/29/25 5:01:27 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2024 Results

      Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

      5/7/24 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

      Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

      4/16/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Financials

    Live finance-specific insights

    See more
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

      Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

      3/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

      BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

      2/24/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 5:49:38 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 9:37:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/12/24 4:49:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care